Form 4: Eloxx Pharmaceuticals Director Receives Stock Option Grant

Director Stephen W. Webster was granted 13,587 stock options in Eloxx Pharmaceuticals as part of standard equity compensation.

Summary

• Director Stephen W. Webster received a grant of 13,587 stock options on June 8, 2026.
• The options have an exercise price of $11.00 per share.
• The options vest in 24 equal monthly installments, becoming fully vested on June 8, 2028.
• The options expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is contingent upon the director's continuous service to the issuer.

Future Outlook

The options vest over a 24-month period, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The 24-month vesting schedule is consistent with standard director compensation packages for small-cap biotech firms.
• The use of stock options as a primary incentive tool aligns with industry norms for early-to-mid-stage pharmaceutical companies.

Corporate Governance

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options in 24 monthly installments starting from June 8, 2026.

Key Dates

Keywords

Eloxx Pharmaceuticals, ELOX, Form 4, Stock Options, Insider Trading, Director Compensation